Efficacy and safety of litifilimab in cutaneous lupus erythematosus: 24-week results of the randomized phase 2 study, AMETHYST. (PubMed, J Am Acad Dermatol) - Oct 19, 2026 - "Litifilimab treatment led to greater improvements in skin disease activity vs placebo and was well tolerated in participants with CLE through Week 24."
Clinical • Journal • P2 data • Cutaneous Lupus Erythematosus • Dermatology • Immunology • Inflammatory Arthritis • Lupus
|
|
; Benjamin F Chong; David Fivenson; Effie Pournara; Eric F Morand; Filippa Nyberg; François Chasset; Hua Carroll; Joseph F Merola; Michael Schindelar; Qianyun Li; Victoria P Werth; Weihong Yang
|